PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1224482
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1224482
Chronic Obstructive Pulmonary Disease Market size was valued at USD 19,607.9 Million in 2022, expanding at a CAGR of 5.8% from 2023 to 2030.
A chronic inflammatory lung disease called chronic obstructive pulmonary disease (COPD) restricts airflow from the lungs. Breathing problems, coughing up mucus, wheezing, and other symptoms are all signs of COPD. In most cases, exposure to noxious gases and particulate matter over an extended period-often from cigarette smoke-is what causes it. If COPD is severe, people may develop heart disease, lung cancer, as well as several other diseases. Emphysema and chronic bronchitis are two common medical disorders that affect COPD sufferers.
Chronic Obstructive Pulmonary Disease Market- Market Dynamics
A significant global health issue, chronic obstructive pulmonary disease (COPD) affects a lot of individuals. The demand for COPD care is growing as the disease burden grows as well. COPD might be brought on by tobacco use. The adult smoking addiction has become more prevalent all over the world. Workplace pollution and indoor air pollution are additional risk factors. The World Health Organization (WHO) claims that exposure to cigarette smoke is the main cause of COPD. The organization estimates that 3.23 million deaths will be caused by chronic obstructive pulmonary disease (COPD), making it the third greatest cause of mortality worldwide. In low- and middle-income nations, COPD fatalities in people under 70 years of age account for about 90% of all mortality (LMIC). Thus, the growing prevalence of COPD across the globe is expected to drive market growth over the forecast period. However, it is projected that the market expansion would be constrained by the high cost of COPD therapy and the lack of awareness about COPD. Additionally, the expiration of patents is a significant barrier for the worldwide industry. Furthermore, throughout the anticipated term, the government's approval for generic medications and biosimilars is anticipated to create enormous market prospects.
Chronic Obstructive Pulmonary Disease Market- Segmentation Analysis:
Based on the COPD type, the global market is segmented into chronic bronchitis and emphysema. The chronic bronchitis segment is expected to hold the largest market share over the forecast period. The growth in the segment is attributed to increased cigarette use, and increased industrialization, which causes air pollution and the release of toxic gases into the environment, which are all contributing to an increase in the incidence and prevalence of chronic bronchitis across the world. For instance, according to the CDC, in 2020, 12.5% of adults in the United States (an estimated 30.8 million individuals) smoked cigarettes: 14.1% of males and 11% of women. Thus, these facts support the segmental growth over the forecast period.
The market is divided into hospitals, clinics, homecare settings, and others based on the end user. The hospital segment is predicted to expand at the fastest CAGR during the forecast period due to an increase in the number of patients suffering from different chronic respiratory illnesses as well as lifestyle disorders, as well as increased awareness about these diseases. Furthermore, the availability of different diagnostics and treatment facilities increased buying power, and the presence of highly skilled healthcare professionals are propelling the worldwide chronic obstructive pulmonary disease market in the hospital segment.
Chronic Obstructive Pulmonary Disease Market- Geographical Insights
In terms of revenue, North America leads the worldwide market for chronic obstructive pulmonary disease in 2022 and is anticipated to continue to do so for the duration of the forecast period. The increased investment in R&D efforts for the creation of novel medications for the treatment of different chronic respiratory diseases as well as lifestyle conditions is primarily responsible for the revenue rise in the North American market. Besides, the market in the Asia Pacific is anticipated to grow at a significant rate during the forecast period due to factors such as increased focus given to the building projects of healthcare infrastructure, an increase in the prevalence of various chronic respiratory diseases as well as lifestyle diseases, an increase in industrialization, changes in lifestyle, and an increase in the number of patients suffering from COPD in developing countries like China and India.
Chronic Obstructive Pulmonary Disease Market- Recent Development:
In July 2020, Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide, and mometasone furoate [IND/GLY/MF]) was approved by the European Commission (EC) as a maintenance treatment for adult patients with asthma whose symptoms were insufficiently controlled by a maintenance regimen involving a long-acting beta2-agonist (LABA) and a high dose of an inhaled corticosteroid (ICS).
Key features of the study:
This proposed research study on the Chronic Obstructive Pulmonary Disease market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains an attractive investment proposition matrix for ` the Chronic Obstructive Pulmonary Disease market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain the Chronic Obstructive Pulmonary Disease market
The impact of COVID-19 on the Chronic Obstructive Pulmonary Disease market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight into the Chronic Obstructive Pulmonary Disease market post-COVID will also be covered.
To give the users of this report a comprehensive view of the Chronic Obstructive Pulmonary Disease market, we have also included a competitive landscape and key innovator analysis for the Chronic Obstructive Pulmonary Disease market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand the financial information and strategic initiatives of players operating in the Chronic Obstructive Pulmonary Disease market.
In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launches, research & development, and regional expansion of major participants involved in the market on global as well as regional levels.
The global Chronic Obstructive Pulmonary Disease market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET KEY PLAYERS
Biomarck Pharmaceuticals
AstraZeneca
Amgen
Afimmune
Boehringer Ingelheim Pharmaceuticals
Chiesi Farmaceutici S.p.A.
Genentech
Circassia Pharmaceuticals Inc.
GlaxoSmithKline
Inmunotek
Mereo BioPharma
Innoviva
Novartis Pharmaceuticals
GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY COPD TYPE
Chronic Bronchitis
Emphysema
GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY TREATMENT
Drugs
Oxygen Therapy
Surgery
Others
GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY END USER
Hospitals
Clinics
Homecare Settings
Others
GLOBAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA